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The immunosuppressant azathioprine is used to prevent graft rejection after organ transplantation. To investigate whether
azathioprine-associated mutagenesis contributes to the high incidence of skin tumours in organ transplant recipients (OTRs), we
analysed PTCH gene mutations in 60 basal cell carcinomas (BCC); 39 from OTRs receiving azathioprine and 21 from individuals never
exposed to azathioprine. PTCH was mutated in 55% of all tumours, independent of azathioprine treatment. In both the azathioprine
and non-azathioprine groups, transitions at dipyrimidine sequences, considered to indicate mutation by ultraviolet-B radiation,
occurred frequently in tumours from chronically sun-exposed skin. In BCC from non-sun-exposed skin of azathioprine-treated
patients, there was an over-representation of unusual G:C to A:T transitions at non-dipyrimidine sites. These were exclusive to the
azathioprine-exposed group and all in the same TGTC sequence context at different positions within PTCH. Meta-analysis of 247
BCCs from published studies indicated that these mutations are rare in sporadic BCC and had never previously been reported in this
specific sequence context. This study of post-transplant BCC provides the first indication that azathioprine exposure may be
associated with PTCH mutations, particularly in tumours from non-sun-exposed skin.
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Keratinocyte skin cancer (KSC) is the most common form of
malignancy following solid organ transplantation. Up to 70% of
fair-skinned solid organ transplant recipients (OTRs) will even-
tually develop KSC of whom two-thirds will have multiple tumours
(Euvrard et al, 2003). Among these patients, the incidence of
squamous cell carcinoma (SCC) is 4100-fold higher than in the
general population. They also have a significantly elevated (410-
fold) risk of basal cell carcinoma (BCC) (Euvrard et al, 2003).
Epidemiological and limited molecular data implicate exposure to
solar ultraviolet radiation (UVR) and the duration of immuno-
suppressive treatment in the development of transplant-related
KSC (McGregor et al, 1997; Euvrard et al, 2003; Queille et al, 2007).
The ultraviolet-B (UVB, 280–320nm) component of UVR is a
known mutagen that causes transition mutations predominantly
at dipyrimidine sequences (Brash et al, 1991). It also activates
signalling pathways that enhance selection of neoplastic cells as
well as suppressing immunity (de Gruijl, 1999; Dlugosz et al, 2002;
Ullrich, 2005). Some commonly used immunosuppressants are
carcinogens (IARC, 1987, 1990), although the extent to which
impaired immune surveillance per se and long-term exposure to
carcinogenic immunosuppressant drugs contribute to KSC in OTR
is unknown.
The thiopurine pro-drug azathioprine (Aza) is a widely used
immunosuppressant. Azathioprine causes 6-thioguanine (6-TG) to
be incorporated into DNA where it can become methylated to
produce a potentially promutagenic DNA lesion (Swann et al,
1996) or interact with UVA (320–400nm). We have previously
shown that, in the latter photochemical reaction, biologically
relevant doses of UVA combine with DNA 6-TG and molecular
oxygen to generate mutagenic reactive oxygen species and at least
one novel and potentially promutagenic DNA lesion, guanine-6-
sulphonate (GSO3) (O’Donovan et al, 2005; Karran and Attard,
2008). The combination of DNA 6-TG/UVA is mutagenic in
cultured cells (O’Donovan et al, 2005). Photochemical DNA 6-TG
damage also occurs in the clinical situation, and the skin of
patients taking azathioprine is selectively hypersensitive to UVA
(O’Donovan et al, 2005; Perrett et al, 2008). On the basis of these
findings, we now examine the hypothesis that azathioprine may
contribute directly to post-transplant cutaneous carcinogenesis.
Molecular analysis in KSC has largely centred on the TP53 gene,
in which characteristic UVB signature mutations have been
reported in up to 90% of sporadic SCC (Ziegler et al, 1994) and
60% of BCC (Ponten et al, 1997). Ultraviolet-B signature mutations
have also been identified in the PTCH gene in BCCs (Gailani et al,
1996; Wolter et al, 1997; Lindstrom et al, 2006; Heitzer et al, 2007),
and the mutational inactivation of PTCH, rather than TP53,i s
likely to be rate limiting for BCC. The PTCH tumour suppressor
gene is located on chromosome 9q22, and germline mutations are Received 6 June 2008; revised 27 August 2008; accepted 27 August 2008
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sfound in the autosomal dominant condition nevoid BCC (Gorlin)
syndrome (NBCCS, MIM 109400), in which patients typically
develop numerous BCCs, usually from an early age (Hahn et al,
1996; Johnson et al, 1996). PTCH is also mutated in up to 70% of
sporadic BCC (Gailani et al, 1996; Hahn et al, 1996; Johnson et al,
1996; Unden et al, 1996; Wolter et al, 1997; Aszterbaum et al, 1998;
Ratner et al, 2001; Zhang et al, 2001; Kim et al, 2002; Reifenberger
et al, 2005; Teh et al, 2005; Heitzer et al, 2007). Germline PTCH
mutations in NBCCS are distributed throughout the entire gene
and the majority cause protein truncation (Wicking et al, 1997). In
BCC from NBCCS, the remaining PTCH allele is deleted or
inactivated by mutation (Gailani et al, 1996). Up to 70% of
acquired PTCH mutations are UVB-type G:C to A:T transitions or
tandem mutations at dipyrimidine sequences (Lindstrom et al,
2006; Heitzer et al, 2007).
PTCH encodes a component of Hedgehog (HH) signalling, a
fundamental developmental signal transduction pathway that also
controls epidermal cell proliferation. PTCH comprises 23 exons
spanning approximately 50kb and encodes a 1447-amino acid
12-transmembrane domain glycoprotein that binds Sonic hedge-
hog (SHH), a secreted ligand regulating proliferation and pattern-
ing of multiple tissues during embryogenesis. Current models
propose that PTCH inhibits HH signalling through interaction
with the Smoothened (SMOH) protein (Bale and Yu, 2001) thereby
repressing expression of the Gli1 and Gli2 transcription factors,
which are themselves key mediators of HH signalling (Dahmane
et al, 1997; Regl et al, 2002). PTCH repression of SMOH is relieved
upon binding of SHH to PTCH resulting in the activation of Gli1
and Gli2 and several other genes including, for example, TGF-beta,
Wnt, BCL-2 (Regl et al, 2002), basonuclin (Cui et al, 2004) and the
forkhead transcription factors FOXMI (Teh et al, 2002) and FOXE1
(Eichberger et al, 2004). Temporally and spatially constrained SHH
signalling regulates cyclic growth of hair follicle epithelium, but
mutational inactivation of PTCH, or activating mutations in SMOH
or SHH, leads to constitutive HH signalling (Unden et al, 1996; Oro
et al, 1997; Xie et al, 1998; Bale and Yu, 2001). The resulting
sustained proliferation drives the development of BCC and other
follicle-derived tumours.
To investigate the role of azathioprine in the development
of transplant-related BCC, we compared the PTCH mutation
spectrum in sporadic BCC from patients immunosuppressed with
azathioprine to the spectrum from individuals not exposed to
azathioprine. The relative genetic homogeneity of BCC makes it a
more tractable experimental system for molecular analysis than
the genetically heterogeneous SCC (Quinn et al, 1994; Ashton et al,
2005; Purdie et al, 2007). In addition, the potentially rate-limiting
nature of PTCH inactivation is likely to be relevant to key
mutational events in BCC. In this first study of post-transplant
BCC, we report differences in the PTCH mutational spectrum that
we propose might reflect a direct influence of azathioprine
exposure on BCC development.
MATERIALS AND METHODS
Patients and samples
Our institution has a dedicated OTR skin clinic in which over
1000 OTRs have been under surveillance since 1989 (Harwood
et al, 2006; Ismail et al, 2006). Patients are seen within 12 months
of transplantation and at least annually thereafter. Basal cell
carcinomas from azathioprine-exposed individuals were obtained
from this patient group. Thiopurine methyltransferase and
thioguanine nucleotide levels, although useful for predicting
acute myelotoxicity, were not specifically included in this study
because all patients had been on azathioprine for at least 6 months
and had stable haematological parameters. Non-azathioprine-
exposed individuals were recruited from among immunocompetent
(IC) individuals attending general dermatology clinics at the
same institution. Clinical details including duration of transplanta-
tion, immunosuppressive drug history and site of BCC were
documented.
Basal cell carcinomas were defined as sun-exposed (SE) lesions
if they arose on chronically SE sites (head, neck, hands and
forearms). Other sites not chronically SE or only intermittently SE
were defined as non-sun exposed (NSE) and included locations
such as trunk and proximal limbs. Basal cell carcinomas on NSE
are more common in OTRs, accounting for up to one-third of OTR
BCC compared with less than one-fifth of IC BCC (Kanitakis et al,
2003; Harwood et al, 2006).
All 60 tumours were histologically confirmed. Tumour tissue
was collected at the time of surgery, immediately snap frozen and
stored at  701C. DNA was extracted by a standard phenol–
chloroform–isoamyl alcohol technique followed by ethanol
precipitation. Matched whole blood samples were obtained for
32 tumours and DNA was extracted by Nucleon DNA extraction
kit (Scotlab, Lanarkshir, UK).
Ethical approval for this study was obtained from the East
London and City Health Authority Ethics Committee. All patients
provided written informed consent. The study was conducted
according to the Declaration of Helsinki Principles.
Mutation detection
An initial mutation screening of exons 2–23 of PTCH was
performed by melting curve analysis (MCA). This study used
MCA as a primary mutation screening technique before DNA
sequencing. This technique has earlier been shown to be a highly
sensitive and specific method for mutation screening (Reed and
Wittwer, 2004). Melting curve analysis generates qualitative data;
therefore, the nature and locations of mutations was confirmed by
DNA sequencing.
PCR was performed in the presence of LCGreenþ, a double-
stranded DNA-binding dye. PCR products were then melted
on a LightScanner (Idaho Technologies, Salt Lake City, UT, USA).
As the DNA melted, LCGreenþ was released and there was
a reduction in the level of fluorescence. Measurement of
differences in the rate of change of fluorescence allowed detec-
tion of variations. Melting curve analysis results were scored
by two independent scientists. Exon 1B was not screened as
the high GþC content of this exon did not permit reliable
analysis. Amplification and analysis of exons 2 and 23 in two
fragments resulted in the generation of less complex melting
profiles and therefore increased the sensitivity of MCA for these
exons.
PCRs for MCA contained PCR buffer, 200mM dNTPs, MgCl2
as required (Supplementary Table 1 online), 1ml LCGreenþ (all
Idaho Technologies), 0.25U of ThermoStart Taq polymerase
(ABgene, Epsom, UK), primers as required, DMSO to a final
concentration of 5%, 20ng of genomic DNA and sufficient water to
make a final volume of 10ml. Thermal cycling conditions were
951C for 12min to activate the Taq polymerase followed by 45
cycles of 941C for 10s, annealing temperature (Supplementary
Table 1 online) for 15s and 721C for 15s. To ensure maximum
incorporation of LCGreenþ into double-stranded amplified DNA,
PCR products were heated to 941C for 30s and allowed to cool to
251C at 0.11C per second. PCR primer sequences and amplification
conditions for each amplified fragment are shown in Supplemen-
tary Table 1 online. Variations detected by MCA were then fully
characterised by DNA sequencing with a version 1.1 BigDye
Terminator kit (Applied Biosystems, Warrington, UK) and
analysed on an Applied Biosystems 3730.
DNA and protein numbering was based on the following
GenBank accessions: genomic DNA AL161729, cDNA NM_000264
and protein NP_000255. Mutations and single-nucleotide poly-
morphisms were compared with the GenBank database, the
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sTable 1 Clinical details of patients and tumours
BCC ID Sex
Age
(years)
a
Immune
status Aza
b
Duration of transplant/
Aza exposure (months)
c
Other IS
drugs Location SE/NSE
d BCC subtype
2 M 61.2 IC N — — Back NSE Nod
4 F 72.4 IC N — — Thigh NSE Nod
6 M 67.2 IC N — — Leg NSE Nod
10 M 49.2 IC N — — Back NSE Nod
1 F 81.8 IC N — — Temple SE Nod
3 M 83.2 IC N — — Ear SE Nod
5 M 57.4 IC N — — Temple SE Nod
7 F 68.4 IC N — — Forehead SE Nod
8 F 83.9 IC N — — Nose SE Nod
11 M 87.2 IC N — — Forearm SE Nod
12 F 83.5 IC N — — Cheek SE Nod
13 M 73.3 IC N — — Nose SE Nod
14 M 72.6 IC N — — Upper lip SE Nod
15 M 82.5 IC N — — Temple SE Nod
16 F 89.2 IC N — — Chin SE Nod
17 M 82.5 IC N — — Cheek SE Nod
18 M 85.9 IC N — — Cheek SE Nod
19 F 75.0 IC N — — Forehead SE Inf
20 M 59.6 IC N — — Nose SE Nod
9 M 61.3 IC N — — Temple SE Nod
58 M 59.1 OTR N 127/  P,C Temple SE Nod
21 M 52.5 OTR Y 137 P Shoulder NSE Sup
24 M 47.9 OTR Y 247 P Shoulder NSE Sup
27 M 59.4 OTR Y 247 P Chest NSE Nod
28
e M 54.8 OTR Y 171 P Mid-back NSE Sup
31 M 42.9 OTR Y 239 P Shoulder NSE Nod
32 M 57.6 OTR Y 24 P,C L Shin NSE Nod
35 F 62.9 OTR Y 296 P Thigh NSE Sup
37 M 47.7 OTR Y 200 P Flank NSE Nod
38 M 48.2 OTR Y 68 P Lower leg NSE Nod
39 M 49.0 OTR Y 175 P,C Upper back NSE Sup
40 M 59.8 OTR Y 155 C Back NSE Nod
49
f M 63.2 OTR Y 104 P,C Scapula NSE Nod
51 M 53.7 OTR Y 108 P,C Lower back NSE Sup
55 M 46.6 OTR Y 135 P,C Shoulder NSE Nod
56 F 38.6 OTR Y 113 P,C Shoulder NSE Nod
57
e M 54.8 OTR Y 171 P Shoulder NSE Sup
59 F 66.0 OTR Y 86 P Elbow NSE Nod
60 M 56.8 OTR Y 28 P,C Mid-back NSE Nod
22 M 71.2 OTR Y 56 P,C Temple SE Nod
23 F 65.6 OTR Y 78 P,C Forehead SE Nod
25 M 58.7 OTR Y 212 P Forearm SE Nod
26 M 58.1 OTR Y 65 P Forehead SE Nod
33 M 79.0 OTR Y 68 P,C Post-auricular SE Nod
36 F 70.0 OTR Y 135 C Forehead SE Nod
41 F 68.2 OTR Y 6 P,C Chin SE Nod
43 M 65.4 OTR Y 75 P.C Forehead SE Nod
44 M 70.9 OTR Y 111 P,C Ear SE Inf
46 M 67.4 OTR Y 100 P,C Temple SE Nod
48
f M 63.2 OTR Y 104 P,C Cheek SE Nod
52 M 65.6 OTR Y 269 P Dorsum hand SE Nod
53 M 74.8 OTR Y 189 P Nose SE Nod
54 M 54.6 OTR Y 99 P,C Nose SE Nod
30 M 53.0 OTR Y 84 P,C Neck SE Nod
34 M 51.3 OTR Y 133 P,C Nose SE Sup
29 M 51.1 OTR-F Ex 168/168 P,C Temple SE Nod
42 M 49.6 OTR-F Ex 156/156 P Scapula NSE Nod
45 M 66.3 OTR Ex 227/84 P, C Chin SE Nod
47 M 54.5 OTR Ex 192/48 P,C Neck SE Nod
50 M 71.2 OTR Ex 141/114 P,C Ear SE Nod
Aza¼azathioprine exposure; BCC¼basal cell carcinoma; C¼ciclosporin; CIS¼squamous carcinoma in situ (Bowen’s disease); Ex¼previously on azathioprine; F¼female;
IC¼immunocompetent individual; inf¼infiltrative BCC; IS¼immunosuppressive; M¼male; nod¼nodular BCC; NSE¼non-sun-exposed site; P¼prednisolone; sample
ID¼sample identification number; SCC¼squamous cell carcinoma; SE¼chronically sun-exposed site; sup¼superficial BCC; OTR¼organ transplant recipient; OTR-F¼failed
organ transplant.
aAge at removal of BCC (years).
bAzathioprine exposure: Y, currently exposed; Ex, previously exposed to azathioprine, but not at the time of BCC removal; pt
29, transplant failed and off azathioprine for 3 years before removal of BCC (but maintained on ciclosporin and prednisolone); pt 45, off azathioprine for more than 10 years
before removal of BCC; pt 47, off azathioprine for at least 8 years before removal of BCC; pt 50, off azathioprine for at least 2 years before removal of BCC.
cFor patients on
azathioprine at the time of diagnosis, the duration of transplantation is equivalent to the duration of azathioprine exposure. For patients previously exposed but off azathioprine at
the time of BCC removal, the duration of previous azathioprine exposure was approximately 168 months, 84 months, 48 months and 114 months for patient nos. 29, 45, 47
and 50, respectively.
dAnatomical location of a BCC was classified as ‘sun-exposed’ if it arose on a chronically UV-exposed site (head and neck, dorsum hands and forearms).
BCCs arising on rarely or only intermittently sun-exposed sites were grouped together as ‘non-sun-exposed’.
eSamples 28 and 57 were from the same individual; although
apparently clinically separate, the finding of an identical PTCH mutation raises the possibility that they may represent a single lesion.
fSamples 48 and 49 were from the same
individual.
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publications not yet entered on the PTCH Mutation Database at the
time of this analysis (specifically Heitzer et al (2007)). The effect
of intronic mutations on splicing was predicted using software
at http://www.fruitfly.org/seq_tools/splice.html. Effect of exonic
mutations on exonic splice enhancers was predicted using software
at http://rulai.cshl.edu/tools/ESE/
Statistical analysis
Statistical analysis was performed in Stata (Stata Corp 2003
Statistical Software: Release 9.0: College Station, TX, USA). Formal
comparisons were made using logistic regression where possible.
Multiple samples from the same individual could not be
considered independent. Model-based variance estimates were
therefore inappropriate, and robust sandwich estimates of variance
were used instead. For comparisons of proportions of those with
the unique G:C to A:T transitions at non-dipyrimidine sites, the
numbers were too small to allow the use of logistic regression.
In this case, and others where numbers were not sufficient, the
Fisher’s exact test was used. To preserve independence, we used
Fisher’s exact test on the number of individuals rather than on the
number of samples.
RESULTS
Patients and tumours
Sixty BCCs from 58 individuals (38 OTRs and 20 IC individuals)
were analysed in this study. Detailed patient information is
presented in Table 1.
(a) Azathioprine-exposed individuals (Aza group) comprised 37
OTRs with BCC (30 males, 7 females). The mean age at
sampling was 58.8 years (38.6–79.0 years) and mean duration
of transplantation was 134 months (range 6–296 months).
Thirty-two individuals were currently receiving systemic
immunosuppression with azathioprine and five had previously
received azathioprine, before BCC diagnosis. Additional
immunosuppressants included ciclosporin (n¼24) and pre-
dnisolone (n¼36). Twenty of these azathioprine-exposed
OTRs had a previous history of KSC, 12 out of 37 (32.4%) with
at least one BCC.
(b) Non-azathioprine-exposed subjects (non-Aza group) included
20 IC individuals (13 men, 7 women; mean age 73.9 years) and
one OTR (males; age 69.4 years; duration of transplant 127
months), never exposed to azathioprine. This OTR had three
prior BCCs but none of the IC individuals had a history
of KSC.
Overall, therefore, 39 tumours were from the Aza group in which
two patients each had two separate tumours. There were
21 tumours from non-Aza individuals. The 60 BCCs comprised
50 nodular, 8 superficial and 2 infiltrative/morphoeic subtypes.
Azathioprine exposure and the frequency and location of
PTCH mutations
There were no germline PTCH mutations in any of the individuals
examined. PTCH mutations were detected in 33 out of 60 (55%)
BCC overall. Azathioprine exposure did not influence this
frequency. A total of 17 mutations were found in 11 out of 21
(52%) non-azathioprine-exposed BCCs (Table 2) vs 27 mutations
from 21 out of 39 (54%) azathioprine-exposed BCCs (Table 3).
Table 2 PTCH mutations in BCC from non-azathioprine-exposed individuals
BCC ID
Exon/intronic
position
Variation in
genomic DNA
a,b Sequence context
Variation in
protein
c
PTCH
domain Effect
d
3 IVS18+5 g.102844 G4T tgagtgt — — Possible effect on splicing
5 Exon 14 g.91889 G4T gctgagc p. E680X ICL3 Nonsense mutation
7 Exon 12 g.84793_84801del ttcccgctctgcggg p. P568_R570
delins R
TM5 3-amino-acid deletion, arginine at position 568
IVS5-1 g.80263 G4A gcagagg — — mRNA splicing
9 IVS8 and exon 9 g.82662_82677del accacaggtggttcatcagagt See below
f — See below
f
12 Exon 15 g.93597 C4T cacccag p. T807T ECL2 Silent variant; possible effect on exonic splice
enhancer
g.93598 C4T Single tandem mutation p. Q808X Nonsense mutation
14 Exon 3 g.75133 C4T ctccagg p. Q184X ECL1 Nonsense mutation
Exon15 g.93653 del T gtttcag p. F826S fsX4 ECL2 Stop codon at position 829
15 Exon 9 g.82774 del G
(homozygous)
cgcgtgg p. V442W fsX14 TM2 Stop codon at position 455
16 Exon 16 98986 A4G tcgacat p. D898G ECL2 Missense mutation; possible effect on exonic
splice enhancers
IVS9+1 g.82798 G4A atggtaa — — RNA splicing
17 Exon 18 g.102581 del G cgagtat p. E970D fsX25 ECL2 Stop codon at position 994
19 IVS21-27 g.111502 C4T acacttt — — See below
e
IVS8-6 g.82660 C4A tgaccac — — No effect on splicing predicted
20 Exon 10 g.83283_83287del tttcctttaac p.S494X ECL3 Stop codon at position 494
58
g Exon 12 g.84724 G4A caggagc p. G545E ICL2 Missense, possible effect on exonic splice
enhancers
Exon 13 g.90996 C4T tatcgac p. R602X ICL3 Nonsense mutation
bp¼base pair; del¼deletion; fs¼frameshift; ins¼insertion; IVS¼intron; PTCH domains: ECL1¼extracellular loop 1; ECL2¼extracellular loop 2; ICL3¼intracellular loop 3;
TM2¼transmembrane 2; TM5¼transmembrane 5.
aMutations are corrected for SNPs (using SNPs from blood samples for BCCs 1–12 and from SNP database for BCCs
13–20 and 58)
bNumbering based on GenBank genomic DNA sequence AL161729.
cApplicable to exonic variants only. Protein numbering based on GenBank accession
number NP_000255.
dEffect of intronic mutations on splicing was predicted using software at http://www.fruitfly.org/seq_tools/splice.html; effect of exonic mutations on exonic
splicing enhancers was predicted using software at http://rulai.cshl.edu/tools/ESE/.
eSplice-site prediction software failed to detect the wild-type splice acceptor site in intron 21
and, therefore, could not predict the effect of any of these variations on splicing.
fThis 16-bp deletion deletes the last 4bp of intron 8 and the first 12bp of exon 9. The deletion of
4bp from intron 8 is predicted to have an effect on splicing. The in-frame deletion of 12bp of exon 9 deletes four amino acids from the PTCH protein: V406, V407, H408 and
Q409.
gPatient no. 58 is an organ transplant recipient never previously exposed to azathioprine.
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the two groups; intronic mutations accounted for 6 out of 17 (35%)
mutations in the non-Aza group and 9 out of 27 (33%) mutations
in the Aza group (Table 4). Analysis of mutation distribution over
the predicted PTCH protein structure (www.cybergene.se/PTCH/)
identified no significant differences between the Aza and non-Aza
groups. Extracellular loop domains were the most commonly
mutated sites in both the groups accounting for 13 out of 18 (72%)
exonic mutations in the Aza group and 6 out of 11 (55%) in the
non-Aza group. Table 4 summarises the distribution of mutations
on the PTCH protein domains.
Nonsense and stop mutations were the most frequently observed
PTCH mutations, together accounting for 8 out of 17 (47.1%) and
15 out of 27 (55.6%) mutations in non-Aza vs Aza group,
respectively.
PTCH mutation spectra in BCC from azathioprine- and
non-azathioprine-exposed patients
PTCH mutations in azathioprine-exposed patients PTCH muta-
tions were detected in 21 out of 39 (54%) BCCs from OTRs
exposed to azathioprine (Table 3). Seventeen (81%) had a single
mutation and the remainder had between two and four mutations
each. Of the 27 individual mutations, there were 12 (44.4%)
transitions at dipyrimidine sites, consistent with UVB involve-
ment. A further three mutations (11.1%) were G:C to T:A
transversions generally regarded to reflect oxidative damage in
the form of unrepaired DNA 8-oxoguanine. There were five
(18.5%) deletions or insertions, all at non-repetitive sequences. We
also observed four (14.8%) G:C to A:T transitions at non-
dipyrimidine sites (Figure 1). These unusual mutations occurred
in samples 21, 28, 38 and 57 from three patients who were
receiving only prednisolone and azathioprine. Strikingly, although
each mutation was at a different locus in the PTCH gene in each
individual, they shared an identical TGTC sequence context
(Figure 2). Two of these mutations occurred in apparently
independent superficial BCCs (samples 28 and 57, Table 3) that
developed in close proximity on the trunk of a single patient. It is
possible that these were, in fact, contiguous regions of a single
superficial tumour, the entirety of which was not clinically
apparent. Nevertheless, we have considered these clinically distinct
tumours to be of independent origin.
Table 3 PTCH mutations in BCC from azathioprine-exposed patients
BCC ID
Exon/intronic
position
Variation in genomic
DNA
a Sequence context
Variation in
protein
b
PTCH
domain Effect
c
21 Exon 3 g.75061 C4T tcatgatacagaccccta p. Q160X ECL1 Nonsense mutation
24 Exon 20 g.101733-101734 ins AC agcACgtc p. V1137T fsX3 TM11 Stop codon at position 1139
28 Exon 5 g.78881 C4T cgaaattacagtctggga p. Q242X ECL1 Nonsense mutation
30 Exon 6 g.80350 G4A gctggga p. W278X ECL1 Nonsense mutation
33 Exon 2 g.54438 G4A gtgggtg p. W129X ECL1 Nonsense mutation
34 Exon 14 g.91901 G4T tccgaga p. E684X ICL3 Nonsense mutation
35 IVS 2+1 54446 del G aaggtaa — — Splicing
36 Exon 22 g.111703 G4A tacgagg p. E1242K C-term Missense mutation; possible effect on exonic
splice enhancers predicted
38 Exon 17 g.101078 C4T tgactaaacagcgtctgg p. Q905X ECL2 Nonsense mutation
39
d Exon 15 g.93615 del G cccgaat p. N814IfsX16 ECL2 Stop codon at position 829
41 Exon 15 g.93622 C4T atccagc p. Q816X ECL2 Nonsense mutation
44 IVS7-2 g.81703 A4C tgcag cg — — See below
e
IVS7-1 g.81704 G4T tgcag cg — — See below
e
48 IVS8-6 g.82660 C4T tgaccac — — No effect on splicing predicted
51 Exon 18 102581 del G cgagtat p. E970D fsX25 ECL2 Stop codon at position 994
53 Exon 23 g.113735 C4T tcgccgt p. A1380V C-term Missense mutation; possible effect on exonic
splice enhancers predicted
Exon 10 g.83158 T4G tcatgct p. Y452X TM2 Nonsense mutation
54 Exon 3 g.75076 G4T gaagaag p. E165X ECL1 Nonsense mutation
56 IVS11-1 g.84692 G4A ccaggac — — Splicing
Exon 17 g.101230 C4A ctacatg p. Y955X ECL2 Nonsense mutation
IVS21-11 g.111518 C4T atcccct — — See below
f
IVS21-10 g.111519 C4T Single tandem
mutation
— — See below
f
Exon 15 g.93597 C4T cacccag p. T807T ECL2 Silent variant; possible effect on exonic splice
enhancers predicted
57 Exon 5 g.78881 C4T cgaaattacagtctggga p. Q242X ECL1 Nonsense mutation
Exon 13 g.90996 C4T tatcgac p. R602X ICL3 Nonsense mutation
29
g IVS20+1 g.107375 G4A caggtaa — — Splicing
Exon 6 g.80326_80335 del agaaaataaactatca p. K270Ifsx10 ECL1 Stop codon at position 279
45
g IVS21+5 g.111016 G4A tcagtag — — See below
d
47
g IVS7+1 g.80884 G4A caggtaa — — Splicing
del¼deletion; fs¼frameshift; ins¼insertion; IVS¼intron; PTCH domains: ECL1¼extracellular loop 1; ECL2¼extracellular loop 2; ICL3¼intracellular loop 3;
TM2¼transmembrane 2; TM11¼transmembrane 11.
aNumbering based on GenBank genomic DNA sequence AL161729 available at http://www.ncbi.nlm.nih.gov/entrez/
viewer.fcgi?val¼AL161729.27. Mutations are corrected for SNPs using SNPs from blood samples (BCCs 22–39, 48, 49 and 57) and from SNP databases (BCCs 21, 40–47,
50–56, 58–60).
bApplicable to exonic variants only. Protein numbering based on GenBank accession number NP_000255.
cEffect of intronic mutations on splicing was predicted
using software at http://www.fruitfly.org/seq_tools/splice.html; effect of exonic mutations on exonic splicing enhancers was predicted using software at http://rulai.cshl.edu/tools/
ESE/.
dIn sample 39, the genomic variation C113540T in exon 23 (c. 3944 c4T) was detected in tumour tissue but not in blood. As this is a common SNP, it was not included
here, although may possibly represent a somatic mutation.
ePossible AG to CT tandem change of unknown cause. Splice-site prediction software failed to detect the wild-type
splice acceptor site in intron 7 and, therefore, could not predict the effect of this variation on splicing. However, as both of these variations are in the intron 7 splice acceptor site,
they are likely to have an effect on splicing.
fSplice-site prediction software failed to detect the wild-type splice acceptor site in intron 21 and, therefore, could not predict the
effect of any of these variations on splicing.
gPatient nos. 29, 45 and 47 had previously been exposed to azathioprine, but not for 2 years before the removal of BCC (see table 2
for details).
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mutations were identified in 12 out of 21 (57.1%) BCCs from
patients never treated with azathioprine (20 IC individuals and one
OTR) (Table 2). Seven of these tumours (58.3%) contained a single
mutation and five each contained two. Of the 17 individual
mutations, seven (41.2%) UVB signatures at dipyrimidine sites
comprised the largest single group. Three (17.6%) were G:C to T:A
transversions, indicating a similar frequency of oxidation-related
mutations as in the Aza group. There were six (35.3%) deletions of
between 1 and 10 bases in moderately repetitive or non-repetitive
sequences. We did not observe any of the G:C to A:T transitions at
non-dipyrimidine sites that were found in the Aza group (Figure 1).
To examine the possible cumulative effects of azathioprine
treatment on mutation type, the Aza-treated group was divided
into two subgroups, having received greater or less than 120
months of azathioprine treatment. Of 15 mutations in the group
exposed for less than 120 months, 8 were UVB type. Among those
more extensively exposed (4120 months) there were 4 (of 12). The
difference in UVB-type mutations between the two groups is not
statistically significant (P-value¼0.571; adjusted for sun exposure,
sex and clustering within individuals). Three of the four G:C to A:T
transition mutations at non-dipyrimidine sites, exclusive to the
azathioprine-exposed group, were in patients exposed for 4120
months.
The effect of additional immunosuppressants
PTCH mutations were equally frequent in BCCs from patients
exposed to azathioprine and prednisolone (7 out of 15, 47% BCC)
and in the group treated with ciclosporin in addition to
azathioprine and prednisolone (14 out of 24, 58.3% BCC). At the
time of tumour removal, two patients in the ciclosporin and Aza
group had discontinued prednisolone. The majority of mutations
in the group exposed to all three immunosuppressants were of the
UVB type (11 out of 19, 57.9% individual mutations). In the
azathioprine plus prednisolone group, only one of eight (12.5%)
mutations was a UVB type and this group contained all four of the
G:C to A:T transitions at non-dipyrimidine sites. The apparently
lower frequency of UVB-type mutations in the azathioprine/
prednisolone group may simply reflect the imbalance between SE
and NSE BCCs in the two groups as six (of eight) individual
mutations in the azathioprine/prednisolone group were from BCCs
on NSE sites.
PTCH mutations and sun exposure
Although the involvement of UVB mutagenesis in PTCH of BCCs
from IC individuals has previously been reported, nothing is
known about the role of UVB in BCC from azathioprine-treated
patients. To address the latter point, we specifically examined
Table 4 Comparison of the overall PTCH mutation frequency, exon/
intron ratio and the distribution throughout the PTCH transmembrane
protein.
Azathioprine
exposed n (%)
Non-azathioprine
exposed n (%)
Total BCC 39 21
BCC with PTCH mutation 21 11
Total PTCH mutations 27 17
Intronic mutations 9 (33%) 6 (35%)
Exonic mutations 18 (67%) 11 (65%)
Distribution in PTCH protein ECL2 6 ECL2 4
ECL1 7 ECL1 1
Carboxy-terminal 2 ECL3 1
ICL3 1 ICL3 2
TM2 1 TM2 1
TM11 1 TM5 1
ICL2 1
ECL1¼extracellular loop 1; ECL2¼extracellular loop 2; ECL3¼extracellular loop 3;
ICL3¼intracellular loop 3; ICL2¼intracellular loop 2; TM2¼transmembrane 2;
TM5¼transmembrane 5; TM 11¼transmembrane 11.
UVB
G:C>A:T at non-dipy site
Oxidation
Ins/del
Other
Azathioprine-exposed mutations (n=27)
Non-azathioprine-exposed mutations (n=17)
Figure 1 PTCH mutation spectra in BCC from azathioprine- and non-
azathioprine-treated patients. A similar proportion of UVB and oxidation-
type mutations is present in each group. The G:C to A:T transition
mutations at non-dipyrimidine sites (hatched) occured exclusively in the
azathioprine-exposed group. These were all within the same TGTC
sequence in different locations within PTCH.
g.75061 C>T Patient 21
Wild-type control
g.78881 C>T  Patient 28
Wild-type control
T C A A T CA C G A T T CCC A G A N A C T AAAG
T C A A T CA C G A T T CCC A G A C A C T AAA G
G C G AAA TT A N A G T C G T GG A C
G C G AAA TT A C A G T C G T GG A C
Figure 2 Sequencing data in BCC from azathioprine-exposed indivi-
duals. (A) Mutation in PTCH exon 3 (g.75061 C4T, c.478 C4T, p.
Q160X). Data from patient BCC ID 21 (top) and from a wild-type control
(bottom). (B) Mutation in PTCH exon 5 (g.78881 C4T, c. 724 C4T, p.
Q242X). Sequencing data are from patient BCC ID 28 (top) and from a
wild-type control (bottom).
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BCCs are more common on NSE skin in OTR than in IC
individuals, it is plausible that the effects of immunosuppressants
are more apparent in the absence of chronic UVB exposure. To
increase the chances of detecting azathioprine-related mutations,
we therefore chose to examine more NSE BCC from the Aza group
(the ratio of SE to NSE tumours in the Aza group was
approximately 1:1 compared with 4:1 in the non-Aza group).
Of the 60 BCCs analysed, 37 had occurred on SE sites. Of these,
20 were from azathioprine-treated patients and 17 from non-Aza
patients. PTCH mutations occurred at similar frequencies in the
two groups (60 and 70.6%, respectively). As expected, UVB
mutations were the largest single mutational class in the non-Aza
BCC and one or more mutations of this type were found in 6 out of
12 (50%). Ultraviolet-B mutations were also the predominant class
in azathioprine-treated patients and were found in 9 out of 12
(75%) BCC in this group.
There were only four NSE BCCs from the IC patients, none of
which contained a mutated PTCH. Of the 37 BCCs in the
azathioprine-treated group, 19 were from NSE skin. Nine
(47.4%) of these NSE BCCs contained a PTCH mutation but only
one was a UVB type. In contrast, C to T transitions at non-
dipyrimidine sites in a TGTC sequence comprised almost half
(four out of nine) of the mutations in this azathioprine-treated
group. The significant (P¼0.02) over-representation of these
mutations in NSE BCC suggests that they are unrelated to sunlight
exposure and this route to PTCH inactivation is more likely in BCC
on NSE skin of azathioprine-treated patients in which the
contribution of UVB is minimised.
Discussion
To our knowledge, PTCH mutations in BCCs from immunosup-
pressed OTR have not previously been systematically investigated.
PTCH was mutated in around half (55%) of the BCCs examined,
and this was independent of immune status and azathioprine
treatment. This frequency is comparable with the known PTCH
mutation frequency in BCCs from the general population. A recent
comprehensive study (Heitzer et al, 2007) found PTCH to be
mutated in 29 out of 60 tumours (48%). We carried out a meta-
analysis of 11 studies in BCCs from presumed IC individuals
published between 1996 and 2007 (Gailani et al, 1996; Hahn et al,
1996; Johnson et al, 1996; Unden et al, 1996; Wolter et al, 1997;
Aszterbaum et al, 1998; Ratner et al, 2001; Zhang et al, 2001; Kim
et al, 2002; Reifenberger et al, 2005; Heitzer et al, 2007). This
revealed that 105 out of 247 (42.5%) tumours had at least one
defined PTCH mutation. It appears that PTCH mutation occurs at
a similar high frequency in BCCs from both IC and immunosup-
pressed individuals.
The contribution of high-intensity sunlight exposure to BCC
development in the general population is well established (Pelucchi
et al, 2007). Compelling evidence for the involvement of UVB
radiation comes from the prevalence of transitions at dipyrimidine
sites that are generally regarded as signature UVB mutations.
Heitzer et al, report that almost 70% of exonic PTCH mutations in
sporadic BCC were of this type. This incidence of UVB signature
mutations is somewhat higher than the frequencies reported in
other studies. Our meta-analysis, while confirming the high
frequency of PTCH mutations, revealed that UVB-type mutations
were present in half (51.4%) of the BCCs. Our analysis of BCC from
immunosuppressed OTR demonstrated that UVB signatures
were the predominant mutational class and comprised almost
half of all PTCH mutations in the azathioprine-exposed (44.4%)
group. The frequency was the same (41.2%) in the non-azathio-
prine-treated control group. These combined data affirm the
relative genetic homogeneity of sporadic BCC of diverse clinical
phenotype, the predominant causative role of UVB-induced DNA
damage and the relatively minor contribution of oxidative DNA
damage.
There are differences in the anatomical distribution of BCCs in
immunosuppressed OTRs and those in the general population.
Both develop head and neck lesions, but OTRs also have BCCs on
relatively NSE skin, particularly the trunk and limbs (Kanitakis
et al, 2003; Harwood et al, 2006). This has previously been
attributed, at least in part, to ascertainment bias as OTRs are
regularly systematically examined in dedicated transplant clinics.
However, it may reflect the presence of another carcinogen that
would be supported by the PTCH mutation analysis in this series.
The frequency of PTCH mutations in BCCs from NSE skin of
azathioprine-treated patients was similar to that in BCC overall,
but there were quantitative and qualitative differences in the
mutational spectrum that we observed. UV-type mutations were
under-represented, consistent with a lesser role for UVB on sites
receiving either no, or only intermittent, sun exposure. In addition,
we found an unusual class of apparently sequence-related non-
dipyrimidine site transitions in some of these OTR BCCs that
could represent a mutational footprint associated with immuno-
suppressant (presumed Aza) treatment. We acknowledge that
in addition to azathioprine, all patients in the organ transplant
group had also been treated with prednisolone and, in many
cases, ciclosporin. There is little evidence that corticosteroids
are mutagenic (IARC Monographs: Prednisolone, 1987) but
ciclosporin is a recognised human carcinogen (IARC Monographs:
Ciclosporin, 1990). We note, however, that the spectrum of PTCH
mutations in BCCs from our patients taking ciclosporin is closely
similar to that for BCCs in non-immunosuppressed patients.
Our meta-analysis of 247 sporadic BCCs from patients not
receiving azathioprine compared with our own findings suggests
that the frequency of the non-dipyrimidine site transition is
increased by azathioprine treatment. It was present in 4 out of
266 vs 3 out of 37 individuals in the non-Aza and Aza groups,
respectively (P¼0.042; Fisher’s exact test). In addition, the
unusual class of mutations was found in patients whose BCCs
had developed after prolonged Aza exposure, suggesting that it
may be dose related.
Azathioprine, and the related 6-mercaptopurine and 6-TG, have
been in clinical use for more than 50 years. They are not powerful
mutagens or carcinogens, although the incorporation of 6-TG in
place of G in DNA is potentially weakly promutagenic. Substantial
substitution of DNA G by 6-TG is well tolerated by cells and DNA
6-TG is not significantly miscoding during replication. The -SH
group of 6-TG is, however, chemically reactive and cellular DNA
6-TG can become methylated or oxidised. Although likely to be
produced only at low levels, the products of these chemical
reactions – S
6-methyl-TG (S
6-meTG) and GSO3 – are potentially
highly mutagenic. The former miscodes during replication and
directs the incorporation of A–a promutagenic change. Guanine-
6-sulphonate is a severe block to replication and may require the
recruitment of error-prone DNA polymerases to effect bypass
(O’Donovan et al, 2005; Zhang et al, 2007).
In cultured cells, 6-TG/UVA treatment is associated with an
increased frequency of the G:C to C:G transversions (O’Donovan,
2006) consistent with oxidation (Henderson et al, 2003). As
keratinocytes from patients treated with azathioprine contain
measurable DNA 6-TG and their skin is selectively UVA sensitive
(Perrett et al, 2008), we anticipated an increase in oxidation-type
PTCH mutations in BCC from azathioprine-treated patients. We
did not observe this. The reasons for this are unclear, but a
contributory factor may be the relative anoxia of keratinocytes
compared with cultured cells.
This study of PTCH mutation in BCC from azathioprine-treated
organ transplant patients and IC individuals confirms that PTCH is
a major target for inactivation of diverse clinical types in BCC. The
findings demonstrate that the major contribution of UVB radiation
to the inactivation of PTCH in BCC on chronically SE skin is also
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also raise the novel possibility of a different aetiology for
azathioprine-related BCC developing on areas of skin that generally
receive intermittent or no exposure to sunlight. Basal cell
carcinomas arising from NSE skin occur infrequently in IC patients
(Kanitakis et al, 2003) and our panel of BCC included only
four examples. None of these contained a PTCH mutation that
precluded direct comparison of mutations between IC and
azathioprine-treated patients. Furthermore, in our meta-analysis
of BCC from IC patients, the anatomical site of the BCC was
frequently not identified and the number of mutations from BCC
on unequivocally NSE sites was again too small (n¼10) to allow
meaningful comparison. It will be important for the significance
of future studies to ensure that sufficient samples from IC patients
are included.
It seems appropriate to follow up the hypothesis that azathio-
prine contributes to mutation in BCC from NSE areas with a more
extensive study. The TP53 gene represents an alternative to PTCH
as a mutational target. TP53 is mutated in many sporadic BCCs
and a large majority of reported mutations are UVB type (Brash
et al, 1991; Giglia-Mari and Sarasin, 2003; Reifenberger et al, 2005).
The IARC TP53 Somatic Mutation database lists more than
1000 mutations from normal, preneoplastic and neoplastic skin
(Petitjean et al, 2007) although an association with immuno-
suppression is noted in only 26 cases for which the medication is
not specified. We are unable to locate any publications that
specifically address TP53 mutation spectra directly in relation to
azathioprine exposure. In view of our findings with PTCH, it now
seems fitting to examine whether promutagenic effects of
azathioprine contribute to TP53 mutation in BCC in areas of the
skin that are protected from sunlight.
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